Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5 clinical trials
A Safety and Efficacy Study of Ligelizumab in the Treatment of CSU in Japanese Patients Inadequately Controlled With H1- Antihistamines

The purpose of this study is to evaluate the safety and efficacy of ligelizumab in adult Japanese subjects with CSU, who remain symptomatic despite treatment with H1-antihistamines (AHs) at

urticaria
antihistamines
ligelizumab
a 12
  • 4 views
  • 08 Oct, 2020
  • 10 locations
Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab

The purpose of this extension study is to establish efficacy and safety of ligelizumab. This will be assessed in adult and adolescent chronic spontaneous urticaria (CSU) patients who have

urticaria
antihistamines
ligelizumab
  • 0 views
  • 30 Dec, 2020
  • 156 locations
A Phase III Study of Efficacy and Safety of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines

The purpose of this study is to establish efficacy and safety of ligelizumab in adolescent and adult subjects with CSU who remain symptomatic despite standard of care treatment by demonstrating

urticaria
omalizumab
antihistamines
a 12
ligelizumab
  • 539 views
  • 16 Dec, 2020
  • 164 locations
A Phase III Study of Efficacy and Safety of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.

The purpose of this study is to establish efficacy and safety of ligelizumab in adolescent and adult subjects with CSU who remain symptomatic despite standard of care treatment by demonstrating

urticaria
omalizumab
antihistamines
a 12
ligelizumab
  • 614 views
  • 19 Dec, 2020
  • 196 locations
Study of Mechanism of Action of Ligelizumab (QGE031) in Patients With Chronic Urticaria

The purpose of the study is to investigate the mechanism of action for ligelizumab (QGE031) treatment in patients with chronic urticaria. The study has two parts. The study population

electrocardiogram
urticaria
cindu
qge031
a 12
  • 0 views
  • 07 Oct, 2020
  • 1 location